CCNE1 and neoplasm: To study the in vivo anti-tumor activity of the PKMYT1i-ATRi combination, three patient-derived xenograft (PDX) models with CCNE1 amplification were utilized, including two OVCA (WO-19, WO-77) and one EMCA (WU-115) model (Supplementary Fig. S3A, B).